Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.
DGX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 63th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 64.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Quest Diagnostics Inc ended up being:
The company has produced more trailing twelve month cash flow than 82.16% of its sector Healthcare.
Quest Diagnostics Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 12.06% of tickers in our DCF set.
DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than merely 12.06% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ANTM, MCK, DVA, CAH, and ANIP can be thought of as valuation peers to DGX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
In healthcare, Baird still believes that labs are still not getting the respect they deserve. It's responding by raising its 2020 and 2021 models again, incorporating a sequential rise in COVID-19 testing that has the companies ready to "crush" quarterly expectations again. "Some investors remain apathetic about this catalyst," Eric...
Pitt faculty and staff received an email from the University’s COVID-19 Medical Response Office on Thursday afternoon outlining a new COVID-19 testing program through Quest Diagnostics as well as a vaccine and daily health check app update.After interest in surveillance COVID-19 testing of faculty and staff, the University has partnered with Quest Diagnostics to provide… The post Pitt faculty, staff to have access to mail-in COVID-19 tests beginning Monday appeared first on The Pitt News .
Quest Diagnostics (DGX) has entered into an agreement with the Centers for Disease Control and Prevention ((CDC)) to provide genomic sequencing to identify new mutations in, and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19.Financial terms of the agreement are not disclosed. The company will perform the sequencing from its...
Quest Diagnostics has inked an agreement with the US Centers for Disease Control and Prevention (CDC) to provide genomic sequencing to identify new mutations and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19. Quest (DGX) didn’t disclose the financial terms of the collaboration. As part of the agreement, the diagnostics company will help CDC in conducting a large-scale longitudinal genomic survey of the SARS-CoV-2 virus using a random set of samples collected from its labs across the US. Quest will conduct the sequencing from its advanced diagnostics laboratory in San Juan Capistrano, California.